Key result
SAPIEN M3 TMVR achieves 100% technical success and complete MR correction in high-risk patients.
Why the study?
Does transcatheter mitral valve replacement with the Edwards SAPIEN M3 system improve mitral regurgitation and clinical symptoms in high-risk patients ineligible for edge-to-edge repair?
Observational (n=6)
No
Does transcatheter mitral valve replacement with the Edwards SAPIEN M3 system improve mitral regurgitation and clinical symptoms in high-risk patients ineligible for edge-to-edge repair?
Transcatheter mitral valve replacement with the Edwards SAPIEN M3 system is technically feasible and effectively abolishes mitral regurgitation in high-risk patients ineligible for edge-to-edge repair, though close monitoring for conduction disturbances and device thrombosis is required.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Iñarra et al. (2026) conducted an observational in Severe symptomatic mitral regurgitation (n=6). Edwards SAPIEN M3 system was evaluated on Technical success and reduction of mitral regurgitation to none or trace. Transcatheter mitral valve replacement using the Edwards SAPIEN M3 system achieved 100% technical success and complete correction of mitral regurgitation in 6 high-risk patients.
Synapse has enriched 5 related papers. Consider them for comparative context: